Trial reportThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception2011
Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.
Trial report in The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00511199 (A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive), which is not on this map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE)
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Hormonal contraceptives for contraception in overweight or obese women.The Cochrane database of systematic reviews · 2016Pooled it
- Hormonal and intrauterine methods for contraception for women aged 25 years and younger.The Cochrane database of systematic reviews · 2015Pooled it
- Combined oral contraceptive pills for treatment of acne.The Cochrane database of systematic reviews · 2012Pooled it
- A detailed review of pharmacokinetics/pharmacodynamics of progestogens in oral contraception.Frontiers in endocrinology · 2026Review
- Using estrogen and progesterone to treat premenstrual dysphoric disorder, postnatal depression and menopausal depression.Frontiers in pharmacology · 2025Review
- Abnormal uterine bleeding control with combined oral contraceptives: a review comparing ethinylestradiol and natural hormones.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025Review
- Association between the use of oral contraceptives and the occurrence of systemic hypertension: A systematic review with statistical comparison between randomized clinical trial interventions.European journal of obstetrics & gynecology and reproductive biology: X · 2024Review
- A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2.European journal of obstetrics & gynecology and reproductive biology: X · 2024Review
- Experts' view on the role of oestrogens in combined oral contraceptives: emphasis on oestetrol (E4).Frontiers in global women's health · 2024Article
- A Retrospective Observational Study on Telemedicine in Prescribing Low-Dose Pills for Patients with Dysmenorrhea.Telemedicine reports · 2024Article
- Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview.Journal of clinical medicine · 2022Review
- Pilot Data on the Feasibility And Clinical Outcomes of a Nomegestrol Acetate Oral Contraceptive Pill in Women With Premenstrual Dysphoric Disorder.Frontiers in endocrinology · 2021Article
- Obesity and hormonal contraception: an overview and a clinician's practical guide.Eating and weight disorders : EWD · 2020Review
- Influence of Contraception Class on Incidence and Severity of Acne Vulgaris.Obstetrics and gynecology · 2020Article
- Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments.Journal of the American Academy of Dermatology · 2019Review
- Contraception with estradiol valerate and dienogest: adherence to the method.Open access journal of contraception · 2019Article
- Ten Years of Experience in Contraception Options for Teenagers in a Family Planning Center in Thrace and Review of the Literature.International journal of environmental research and public health · 2018Article
- Benefits of reversible contraception.F1000Research · 2018Review
- Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians.The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2016Review
- Nomegestrol acetate/17-beta estradiol: a review of efficacy, safety, and patient acceptability.Open access journal of contraception · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe primary objective was to assess the efficacy, cycle control and tolerability of a monophasic combined oral contraceptive (COC) containing nomegestrol acetate (NOMAC) and 17β-oestradiol (E2). Effects on acne were evaluated as a secondary objective. Results were compared to those of a COC containing drospirenone (DRSP) and ethinylestradiol (EE).
methodsWomen (aged 18-50 years) were randomised to receive NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=1591) or DRSP/EE (3 mg/30 μg) in a 21/7-day regimen (n=535) for 13 cycles.
resultsEstimated Pearl Indices for NOMAC/E2 and DRSP/EE were 0.38 and 0.81 in women aged≤35 years and 0.31 and 0.66 for all women (18-50 years), respectively. Scheduled withdrawal bleedings were shorter and lighter among users of NOMAC/E2 and were sometimes absent altogether. Intracyclic bleeding/spotting was infrequent in both groups, and decreased over time. Type and frequency of adverse events were similar to those typically reported for COCs.
conclusionsThese data show that NOMAC/E2 provides high contraceptive efficacy with acceptable cycle control as well as an overall adverse event profile similar to that of DRSP/EE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.